145
Participants
Start Date
August 31, 2011
Primary Completion Date
October 31, 2014
Study Completion Date
February 28, 2017
Neo-adjuvant Erbitux-based chemotherapy
"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
Eye & Ear Hospital of Fudan University, Shanghai
Fudan University Shanghai Cancer Center, Shanghai
Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai
Shanghai Changzheng Hospital, Shanghai
Shanghai First People's Hospital, Shanghai
Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Tongji University Dongfang Hospital, Shanghai
Fudan University
OTHER
Tongji University
OTHER
Second Military Medical University
OTHER
Shanghai Jiao Tong University School of Medicine
OTHER